Recent 8-K filings for CYRX

• May 4, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Cryoport Q1 revenue $47.8M (+16% YoY); raises FY2026 guidance to $192-196M

  Q1 revenue $47.8M (+16% YoY); commercial CGT revenue $9.1M (+26%).

• March 3, 2026, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Cryoport FY2025 revenue $176.2M (+12% YoY) beats guidance; FY2026 outlook $190-194M

  FY2025 revenue $176.2M, up 12% YoY; Q4 revenue $45.5M, up 10% YoY.

• November 4, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Cryoport Q3 revenue rises 15% to $44.2M; raises FY2025 guidance to $170-174M

  Q3 continuing ops revenue $44.2M (+15% YoY); gross margin 48.2% vs 45.5%.

• August 6, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Cryoport Q2 revenue up 14% to $45.5M; cell & gene therapy revenue +33%; reaffirms FY25 guidance

  Net income of $105.2M includes $117.4M gain from CRYOPDP divestiture; adjusted EBITDA improved to -$0.9M vs -$5.6M a year ago.

• June 13, 2025, 7:59 PM ET M&A materiality 0.75 positive item 2.01item 7.01item 9.01 ◈ M&A Transactions

  Cryoport completes CRYOPDP divestiture to DHL for ~$200M in cash; launches strategic partnership

  Total cash consideration of ~$200M: $133M purchase price plus repayment of $77.2M in intercompany loans.

• May 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Cryoport Q1 revenue $41M, up 10% YoY; cell & gene therapy revenue up 33%

  Commercial Cell & Gene therapy revenue $7.2M, up 33% YoY; supported 19 commercial therapies.

• March 31, 2025, 7:59 PM ET M&A materiality 0.85 positive item 1.01item 7.01item 9.01

  Cryoport sells CRYOPDP to DHL for $195M enterprise value, forms strategic partnership

  Divests CRYOPDP to DHL for total enterprise value of $195M; ~$138M cash plus repayment of ~$67M intercompany loans.

• March 4, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Cryoport reports FY 2024 revenue $228.4M (-2% YoY); guides FY 2025 revenue $240-250M

  FY 2024 revenue $228.4M (down 2% YoY); Q4 revenue $59.5M (up 4% YoY).

• November 7, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Cryoport Q3 revenue flat YoY at $56.7M; services up 9%, product down 14%

  Net loss attributable to common stockholders: $1.2M ($0.02/share) vs $15.3M loss ($0.31) YoY.

• August 6, 2024, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Cryoport authorizes $200M repurchase program; repurchases $160M convertible notes at 11.5% discount

  Board authorized up to $200M repurchase of common stock and/or convertible notes, effective Aug 1, 2024 through Dec 31, 2027.

• August 6, 2024, 7:59 PM ET earnings materiality 0.80 negative item 2.02item 9.01

  Cryoport Q2 net loss $78M including $63.8M goodwill impairment; FY24 guidance cut to $225-235M

  Revenue $57.6M (+1% YoY, +5.5% sequentially); Life Sciences Services up 8%, Products down 10%.

• May 7, 2024, 7:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01 ◈ Earnings Releases

  Cryoport Q1 revenue falls 13% to $54.6M; net loss widens to $18.9M, adjusted EBITDA negative $7.7M

  Life Sciences Products revenue dropped 34% YoY to $17.8M, driven by slowdown in MVE cryogenic systems demand.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.75 · Most common event earnings

7 positive 2 negative 5 neutral

source · CYRX on sec.gov